We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancer Spread Takes More Than a Twist of Fate

By Biotechdaily staff writers
Posted on 13 Jul 2004
Cancer researchers have found that in order to metastasize, cancer cells must activate the gene that codes for the gene regulatory protein Twist. More...
Cancer cells lacking Twist can grow, but they cannot migrate to establish new tumors in distant tissues.

Investigators at the Whitehead Institute for Biomedical Research (Cambridge, MA, USA) used microarray technology to examine patterns of gene activation in metastatic and nonmetastatic cancer cells taken from mouse tumors. They reported in the June 25, 2004, issue of Cell that Twist, a gene regulator normally active in the developing embryo, was functioning in the metastatic cells but not in the nonmetastatic cells.

Further studies revealed that if the Twist gene was inactivated in a normally metastatic tumor, it failed to metastasize after being injected into naïve mice. Twist expression resulted in loss of E-cadherin-mediated cell-cell adhesion, activation of mesenchymal markers, and induction of cell motility. Lacking these influences, Twist-deficient cancers could grow but not spread.

Despite its obvious importance in the process of metastasis, Twist is not the whole story. Senior author Dr. Robert Weinberg, professor of biology at the Massachusetts Institute of Technology (Boston, MA, USA) said, "There are a number of other regulatory proteins that have been studied in other labs and have properties very similar to those of Twist. The other regulators undoubtedly will play important roles in other types of human metastatic cancer.”





Related Links:
Whitehead Institute for Biomedical Research

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Clinical Informatics Platform
CLARION™
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.